ADMA Biologics Inc (NASDAQ: ADMA) has reported E.P.S. of $0.08 for its first fiscal quarter (ending March 31) versus $-0.03 for the same period a year ago. For the latest four quarters through March 31, E.P.S. were $-0.02 compared to $-0.24 a year ago.
Recent Price Action
ADMA Biologics Inc (NASDAQ: ADMA) stock closed at $6.93 on 5/9/24 after an increase of 1.0%. NORMAL trading volume accompanied the advance. The stock has risen 3.9% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, ADMA is expected to be a major Value Builder.
ADMA Biologics has a current Value Trend Rating of A (Highest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. ADMA Biologics has a neutral Appreciation Score of 55 but a very high Power Rating of 98, producing the Highest Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment